by McKesson Ventures | Jun 9, 2018 | Portfolio News
At last weekend’s American Society of Clinical Oncology annual meeting, GRAIL released results of a study that shows the potential for lung cancer to be detected with a blood test. The survey evaluated 127 patients with lung cancer and 580 controls. The researchers...
by McKesson Ventures | Jun 7, 2018 | Portfolio News
At the American Society of Clinical Oncology Annual Meeting on June 4, 2018, GRAIL announced the clinical results from a 127-patient sub-study of its Circulating Cell-free Genome Atlas (CCGA) trial. The analysis revealed that the company’s genome-sequencing blood...
by McKesson Ventures | May 11, 2018 | Media Coverage
Senior vice president and managing director of McKesson Ventures Tom Rodgers reported that the firm broke precedent with its investment in GRAIL Inc. The investment was unusual for the company in two ways; it was one of the firm’s larger spends, and it was also toward...
by McKesson Ventures | Apr 27, 2018 | Portfolio News
In an article for Wonkette, writer Carlos Sagan provides some interesting insights into the recent scientific progresses made in cancer research. Sagan, who has a background in cancer research and drug development, writes in a conversational and off-color way,...
by McKesson Ventures | Apr 26, 2018 | Press Releases
Earlier this month, GRAIL, Inc., a life sciences company dedicated to finding early detection strategies for cancer patients, announced that it has made progress toward developing a method for identifying multiple types of cancer through blood tests. The announcement...
